Showing 301-310 of 20873 results for "".
- Lithocholic Acid: A Translational Pathway to Metabolic Health in Type 2 Diabeteshttps://reachmd.com/news/lithocholic-acid-a-translational-pathway-to-metabolic-health-in-type-2-diabetes/2485401/Lithocholic acid (LCA) shows preclinical benefit for glycemic control in a diet‑plus‑streptozotocin mouse model of type 2 diabetes. C57BL/6 mice given daily oral gavage of LCA (50 mg/kg) for four
- Emerging Roles of SGLT2 Inhibitors and GLP-1 RAs in Managing Gout and Type 2 Diabeteshttps://reachmd.com/news/emerging-roles-of-sglt2-inhibitors-and-glp-1-ras-in-managing-gout-and-type-2-diabetes/2475471/Emerging Roles of Sodium‐Glucose Co-Transporter‐2 (SGLT2) Inhibitors and Glucagon‐Like Peptide‐1 Receptor Agonists (GLP-1 RAs) in Managing Gout and Type 2 Diabetes As clinicians face the dual challenge of managing type
- Maternal Type 2 Diabetes Not Linked to Reduced AD Risk in Children: Studyhttps://reachmd.com/news/maternal-type-2-diabetes-not-linked-to-reduced-ad-risk-in-children-study/2487400/New research suggests maternal type 2 diabetes mellitus (T2DM) does not independently influence the risk of atopic dermatitis (AD) in children. Researchers for a retrospective cohort study analyzed electronic medical and birth records from Clalit Health Services in Israel (n = 314,224 moth
- Real-Time CGM Lowers HbA1c vs SMBG in Type 2 Diabeteshttps://reachmd.com/news/real-time-cgm-lowers-hba1c-vs-smbg-in-type-2-diabetes/2487104/Key Takeaways Lower HbA1c was observed with CGM than with SMBG at both prespecified assessments. The open-label multicentre randomized trial enrolled adults with type 2 diabetes receiving basal insulin plus SGLT2 inhibitors, GLP-1 receptor agonists, or
- Tirzepatide in Type 1 Diabetes: Phase 2 Trial Readouthttps://reachmd.com/news/tirzepatide-in-type-1-diabetes-phase-2-trial-readout/2486814/Key Takeaways Tirzepatide was associated with greater short-term weight loss than placebo in adults with type 1 diabetes and obesity. HbA1c and total daily insulin dose also declined relative to placebo during the 12-week comparison. No signif
- Polygenic Risk Scores and Lifestyle in Japanese Type 2 Diabetes Riskhttps://reachmd.com/news/polygenic-risk-scores-and-lifestyle-in-japanese-type-2-diabetes-risk/2486670/Key Takeaways Higher polygenic risk scores were associated with increased risk of incident type 2 diabetes in Japanese cohorts, with consistent findings across study populations. Favorable lifestyle factors—including regular exercise and absence of hyp
- Tirzepatide Trial In Adults With Type 1 Diabetes Reports Weight Losshttps://reachmd.com/news/tirzepatide-trial-in-adults-with-type-1-diabetes-reports-weight-loss/2486590/Key Takeaways: A randomized 12-week trial in adults with type 1 diabetes and obesity reported greater weight loss with tirzepatide than placebo (estimated treatment difference, -8.7 kg [95% CI, -12.0 to -5.5]; P < 0.0001). Investigators also reporte
- Genetic Drivers of Early-Onset Type 2 Diabetes in South Asians Revealedhttps://reachmd.com/news/genetic-drivers-of-early-onset-type-2-diabetes-in-south-asians-revealed/2468735/A study recently published in Nature Medicine highlights genetic factors that contribute to early-onset type 2 diabetes in South Asians, a population disproportionately affected by the condition. Conducted by researchers at Queen Mary University of London, the study identifies key geneti
- Breastfeeding Linked to Lower Cardiovascular Risk in Women With Type 2 and Gestational Diabeteshttps://reachmd.com/news/breastfeeding-linked-to-lower-cardiovascular-risk-in-women-with-type-2-and-gestational-diabetes/2468566/New research from the Global Centre for Asian Women’s Health (GloW) at the National University of Singapore (NUS) and Harvard T.H. Chan School of Public Health indicates that breastfeeding may be associated with a reduced risk of cardiovascular disease (CVD) among women with type 2 diabetes and g
- New Strategy to Prevent Hypoglycemia in Type 1 Diabetes: Targeting Somatostatinhttps://reachmd.com/news/inhibiting-somatostatin-may-prevent-dangerous-blood-glucose-drops-in-type-1-diabetes/2468364/A recent study from the University of Gothenburg suggests that inhibiting somatostatin, a hormone found in the pancreas, may prevent life-threatening blood sugar drops in people with type 1 diabetes. The research, published in Nature Metabolism, uncovers a novel approach that could poten